TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00919360

Intervention type: PROCEDURE
Intervention: collection of maternal blood specimen prior to delivery
Description: approximately 5 cc. of maternal blood will be drawn prior to delivery

Intervention type: PROCEDURE
Intervention: collection of maternal blood specimen prior to delivery
Description: approximately 5 cc. of maternal blood will be drawn prior to delivery

Intervention type: PROCEDURE
Intervention: collection of placental cord blood after delivery
Description: approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped

Intervention type: PROCEDURE
Intervention: collection of placental cord blood after delivery
Description: approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped

Intervention type: PROCEDURE
Intervention: collection of placental tissue
Description: within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.

Intervention type: PROCEDURE
Intervention: collection of placental tissue
Description: within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.

Intervention type: PROCEDURE
Intervention: collection of strip of decidua from uterine lining from cesarean section deliveries
Description: A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.

Intervention type: PROCEDURE
Intervention: collection of strip of decidua from uterine lining from cesarean section deliveries
Description: A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
Study: NCT04231019

Intervention type: OTHER
Intervention: self-administered questionnaire
Description: Self-administered questionnaires with plain language statements and brief description of the clinical features and photographs of MIH were used to determine the knowledge, awareness and perception regarding the prevalence, severity, etiology and treatment modalities of molar-incisor hypomineralization (MIH) among Egyptian fifth year dental students, general dental practitioners and dental specialists.~There were two routes for delivering the questionnaire either as online questionnaire sent to the participants by email or as a hard copy that is hand delivered.
Study: NCT01887197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorptive clearance scan
Description: Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorptive clearance scan
Description: Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
Study: NCT02487823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide
Description: BKM 120, LH-RH agonists and Bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide
Description: BKM 120, LH-RH agonists and Bicalutamide
Study: NCT04376892

Intervention type: OTHER
Intervention: Quality of life measurement
Description: Quality of life measurement by St. George Respiratory questionnaire
Study: NCT01887197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled hypertonic saline (7%)
Description: nebulized hypertonic saline (7%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mannitol inhalation powder
Description: mannitol inhalation powder
Study: NCT03916419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViewRay MR-Linear Accelerator
Description: -Radiation will be delivered by this machine
Study: NCT03916419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViewRay MR-Linear Accelerator
Description: -Radiation will be delivered by this machine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -60Gy in 15 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -60Gy in 15 fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: -50 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: -50 mg/m\^2 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC
Description: -2 mg/mL/min intravenous over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC
Description: -2 mg/mL/min intravenous over 30 minutes
Study: NCT04376892

Intervention type: OTHER
Intervention: Quality of life measurement
Description: Quality of life measurement by St. George Respiratory questionnaire

Intervention type: OTHER
Intervention: Quality of life measurement
Description: Quality of life measurement by St. George Respiratory questionnaire
Study: NCT01053949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
Study: NCT03916419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: -10 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: -10 mg/kg
Study: NCT02056951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary rehabilitation
Description: Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:~* health education~* exercise therapy~* back school~* physical treatments~* psychological interventions in groups and individual counselling~* rehabilitation/social counselling.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interprofessional rehabilitation
Description: Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:~* education about low back pain~* behavioural exercise therapy~* coping with pain~* relaxation~* work related informations
Study: NCT01053949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
Study: NCT03772990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Chloride
Description: Calcium Chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: 0.9% Sodium Chloride
Study: NCT03734536

Intervention type: DEVICE
Group type: OTHER
Intervention: REGENETEN™ Bioinductive Implant
Description: The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.

Intervention type: DEVICE
Group type: OTHER
Intervention: Arthroscopic repair of the high-grade (>50%) partial-thickness
Description: Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
Study: NCT02685852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide at a dose of 5 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide at a dose of 5 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose at a dose of 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acarbose
Description: Acarbose at a dose of 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide Placebo
Description: Placebo for Exenatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose Placebo
Description: Placebo for Acarbose
Study: NCT02694523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection
Study: NCT02456116

Intervention type: OTHER
Group type: OTHER
Intervention: PCA/NSAID
Description: standard boli of morphine by pressing a button of PCA
Study: NCT00984802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX-2043
Description: Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX-2043
Description: Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX-2043
Description: Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Vehicle solution for IV administration single dose.
Study: NCT01461863

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Porridge protein calorie supplement
Description: 250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin
Description: Standard multivitamin
Study: NCT03403491

Intervention type: OTHER
Group type: OTHER
Intervention: patientMpower application
Description: electronic health journal for patient to record weight, blood pressure, medication adherence and symptoms
Study: NCT02694523

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
Study: NCT03403491

Intervention type: OTHER
Group type: OTHER
Intervention: patientMpower application
Description: electronic health journal for patient to record weight, blood pressure, medication adherence and symptoms

Intervention type: OTHER
Group type: OTHER
Intervention: sham application
Description: dummy application which does not allow recording of weight, blood pressure, medication adherence and symptoms

Intervention type: OTHER
Group type: OTHER
Intervention: sham application
Description: dummy application which does not allow recording of weight, blood pressure, medication adherence and symptoms
Study: NCT02694523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo risankizumab administered by subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo for adalimumab
Description: Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
Study: NCT04877106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg)
Description: The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®, 50mg/850mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
Description: The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
Study: NCT00495664

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titan stent and Taxus-Liberte stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titan stent and Taxus-Liberte stent
Study: NCT01132573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00633828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased physical education in primary school (daily)
Description: Increased physical education in primary school, 40 minutes per day
Study: NCT00713401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecadenoson
Description: Tecadenoson administered intravenously (i.v.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecadenoson
Description: Tecadenoson administered intravenously (i.v.)
Study: NCT01272661

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Curriculum
Description: Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Curriculum+Breastfeeding Doula
Description: In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
Study: NCT00708448

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: Patients will receive an FLT-PET scan, FDG-PET scan, a H215O-PET scan, and have a blood sample (15 cc, approximately 3 teaspoons) drawn for the genetic and protein studies. These studies will be done before patients begin taking erlotinib and bevacizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg q 21 days
Study: NCT03463460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT01272661

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Curriculum +Father Support
Description: In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
Study: NCT01058265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative
Description: Integrative Medicine medical evaluation.
Study: NCT04418505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vielight RX Plus
Description: The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
Study: NCT03487510

Intervention type: OTHER
Intervention: NO interventions apply
Description: does not apply
Study: NCT01058265

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard general medical evaluation.
Study: NCT03505008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Route of Administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Route of Administration: Subcutaneous
Study: NCT01690260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Morphogenetic Protein 2
Description: 12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Morphogenetic Protein 2
Description: 12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone graft
Description: Autologous bone graft in connection with bone docking operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone graft
Description: Autologous bone graft in connection with bone docking operation.
Study: NCT02260674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 10 milligram (mg)
Description: Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
Study: NCT03405753

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia, washout and then placebo
Description: Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
Study: NCT00713401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecadenoson
Description: Tecadenoson administered intravenously (i.v.)
Study: NCT02260674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 50 mg
Description: Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
Study: NCT04585373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio-taping with conventional therapy 24 hours
Description: standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio-taping with conventional therapy 48 hours
Description: standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio-taping with conventional therapy 72 hours
Description: standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa.
Study: NCT04774120

Intervention type: DRUG
Intervention: Propofol
Description: Propofol will be started at a rate of 15-20 mg/kg/hr in patients \>65 years and 20-25 mg/kg/hr in younger patients (\<65 years) until a suppression rate (SR) is achieved. If not, can be increased by 5 mg/kg/hr every 5 minutes up to 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group or after 15 minutes have passed. When the SR appears, propofol infusion will be stopped. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.

Intervention type: DRUG
Intervention: Propofol
Description: Propofol will be started at a rate of 15-20 mg/kg/hr in patients \>65 years and 20-25 mg/kg/hr in younger patients (\<65 years) until a suppression rate (SR) is achieved. If not, can be increased by 5 mg/kg/hr every 5 minutes up to 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group or after 15 minutes have passed. When the SR appears, propofol infusion will be stopped. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
Study: NCT02331875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2201
Description: The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Surgery
Description: After the end of treatment with IPH2201, according to standard recommendations in the relevant country .

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postsurgical Adjuvant Therapy
Description: After the standard surgery, according to standard recommendations in the relevant country
Study: NCT00414921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Clonidine is FDA-approved for the treatment of hypertension in adults

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Clonidine is FDA-approved for the treatment of hypertension in adults

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: Methylphenidate is known to safely and effectively treat many ADHD symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: Methylphenidate is known to safely and effectively treat many ADHD symptoms.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive substance
Study: NCT03408002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: The intervention aims to increase self-efficacy perception in managing pre-operative anxiety. The intervention is based on one single psychological consultation adopting the Four elements technique elaborated by Shapiro